DBV Technologies S.A. (NASDAQ:DBVT) Receives $14.75 Consensus PT from Analysts

Shares of DBV Technologies S.A. (NASDAQ:DBVT) have been assigned a consensus rating of “Moderate Buy” from the five research firms that are covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, three have given a buy rating and one has issued a strong buy rating on the company. The average 1 year price target among analysts that have issued ratings on the stock in the last year is $14.75.

A number of equities analysts recently weighed in on DBVT shares. Wall Street Zen downgraded shares of DBV Technologies from a “hold” rating to a “sell” rating in a report on Friday, July 18th. The Goldman Sachs Group upgraded shares of DBV Technologies to a “sell” rating and set a $7.25 target price on the stock in a report on Thursday, May 29th. Citigroup restated an “outperform” rating on shares of DBV Technologies in a report on Tuesday, May 27th. Lifesci Capital upgraded shares of DBV Technologies to a “strong-buy” rating in a report on Thursday, June 26th. Finally, JMP Securities reaffirmed a “market outperform” rating and set a $21.00 price objective on shares of DBV Technologies in a research report on Thursday, June 26th.

Hedge Funds Weigh In On DBV Technologies

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in DBVT. Boxer Capital Management LLC bought a new position in DBV Technologies during the fourth quarter worth $154,000. Nan Fung Trinity HK Ltd. bought a new position in DBV Technologies during the second quarter worth $340,000. Vivo Capital LLC bought a new position in DBV Technologies during the second quarter worth $9,659,000. MPM Bioimpact LLC bought a new position in DBV Technologies during the second quarter worth $9,649,000. Finally, Adage Capital Partners GP L.L.C. bought a new position in DBV Technologies during the second quarter worth $9,659,000. 71.74% of the stock is owned by institutional investors.

DBV Technologies Trading Up 4.8%

Shares of DBVT opened at $10.00 on Friday. The company has a market cap of $273.90 million, a price-to-earnings ratio of -2.10 and a beta of -0.58. DBV Technologies has a 1-year low of $2.20 and a 1-year high of $12.78. The company’s fifty day simple moving average is $9.81 and its 200 day simple moving average is $7.96.

DBV Technologies (NASDAQ:DBVT) last issued its earnings results on Tuesday, July 29th. The company reported ($1.55) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.21) by ($1.34). The firm had revenue of $1.74 million for the quarter, compared to analyst estimates of $0.64 million. DBV Technologies had a negative return on equity of 287.15% and a negative net margin of 3,220.49%. As a group, research analysts forecast that DBV Technologies will post -7.05 earnings per share for the current year.

About DBV Technologies

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.